Agenus shared on LinkedIn:
“The Agenus team is headed to Barcelona for ESMO24.
This Friday, catch the latest data from our clinical trial of botensilimab and balstilimab in refractory sarcomas.
View the presentation details here.”
Proceed to video attached to post.
Source: Agenus/LinkedIn